Compugen Ltd (CGEN)$2.80
Market Cap: 128.11 MCurrency: USD
Research Snapshot
Static fundamentals, valuation context, and investor signals for Compugen Ltd (CGEN).
HEALTHCARE
BIOTECHNOLOGY
DCF ready
Valuation
1.2x
EV/FCF, 83.5% FCF yield
Quality
34.4%
ROIC, 43.1% FCF margin
Growth
105.2%
5Y sales (revenue) CAGR
Balance sheet
0.0x
Debt/equity, 6.6x current ratio
Superinvestors
1
Top: David Katz (0.0%)
Strengths to research
- Revenue compounded at 105.2% over five years.
- Return on equity is strong at 34.4%.
- Free cash flow margin is healthy at 43.1%.
- Debt/equity looks manageable at 0.0x.
Watchouts
No major valuation, balance sheet, or growth watchouts were detected by the static screen.
Annual data: 10 periods
Quarterly data: 5 periods
Stock snapshot: May 25, 2026
Static dataset: May 25, 2026
Quality Scorecard
Build-time composite score for CGEN.
Grade C
59
/ 100
Peer Comparison
Target stock against 8 market-cap comparable peers.
Heat map: red worst to green best
| CGEN Target | Compugen Ltd | $128.1M | 7.4x | 1.2x | 34.4% | 105.2% | 43.1% | 87.3% | -2.8x | N/A |
| COYA | Coya Therapeutics Inc | $107.2M | -3.8x | -5.6x | -49.3% | N/A | -135.2% | N/A | N/A | N/A |
| DMAC | DiaMedica Therapeutics Inc. | $171.4M | N/A | -5.4x | -58.4% | N/A | N/A | N/A | N/A | N/A |
| INBX | Inhibrx | $178.5M | -11.2x | -0.4x | -1752.2% | N/A | -9986.5% | N/A | N/A | N/A |
| CRBU | Caribou Biosciences Inc. | $79.9M | -1.3x | -0.6x | -121.2% | -2.0% | -1006.8% | N/A | N/A | N/A |
| GUTS | Fractyl Health Inc | $79.8M | -0.5x | 0.0x | -1490.3% | N/A | N/A | N/A | N/A | N/A |
| IVVD | Invivyd Inc. | $69.0M | -3.7x | 2.7x | -21.7% | N/A | -109.1% | N/A | N/A | N/A |
| GANX | Gain Therapeutics Inc. | $56.4M | -2.9x | -1.9x | -106.3% | N/A | N/A | N/A | N/A | N/A |
| PEPG | Pepgen Inc | $47.1M | -0.7x | 0.2x | -60.8% | N/A | N/A | N/A | N/A | N/A |
Financial Charts
No financial data available for CGEN (annual).
1 superinvestors own CGEN
Current quarter ownership and quarter-over-quarter share changes.
Superinvestor ownership
| Fund | Shares | Value | % Portfolio | QoQ Change |
|---|---|---|---|---|
| David Katz Matrix Asset Advisors | 93,833 | $200,000 | 0.02% | 0.0% |